Neos angles for a $74M IPO to fund its ADHD drugs

Neos Therapeutics spelled out the terms of its pending IPO, lining up for as much as $73.6 million as it moves forward with reformulated versions of common ADHD treatments. The biotech intends to price 4 million shares at between $14 and $16 each, setting aside another 600,000 shares for its underwriters to cover overalottments. With the proceeds, Neos plans to get a trio of extended-release, orally dissolving treatments on the market. Its lead candidate, containing the same active ingredient as Ritalin, is up for an FDA decision in November, and Neos plans to submit its two amphetamine-based treatments for approval later this year. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.